Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 3/20 | 0.59 |
| ▸ | GSK3B | P49841 | 3/20 | 0.59 |
| ▸ | ELANE | P08246 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | CTSG | P08311 | 1/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
| ▸ | CTRC | Q99895 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2087484 | 1.00 | GSK3A (0.59) | GSK3AGSK3BELANEF2PLG | |
| SCHEMBL2086997 | 0.82 | GSK3A (0.49) | GSK3AGSK3BELANEF2PLG | |
| SCHEMBL3318940 | 0.75 | GSK3A (1.00) | GSK3AGSK3BELANEF2PLG | |
| SCHEMBL4658933 | 0.72 | GSK3A (0.69) | GSK3AGSK3BELANEF2PLG | |
| SCHEMBL2085483 | 0.72 | GSK3A (0.69) | GSK3AGSK3BELANEF2PLG | |
| SCHEMBL29558351 | 0.70 | GSK3A (0.65) | GSK3AGSK3BELANEF2PLG | |
| SCHEMBL4791747 | 0.70 | GSK3A (0.65) | GSK3AGSK3BELANEF2PLG | |
| Bicarbonate SCHEMBL25171118 | 0.66 | POLB (0.64) | GSK3AGSK3BELANEF2PLG | |
| SCHEMBL10559302 | 0.66 | GSK3A (0.70) | GSK3AGSK3BELANEF2PLG | |
| Hydantoin SCHEMBL4914979 | 0.66 | GSK3A (0.77) | GSK3AGSK3BELANEF2PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053918-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-03-03 | — | — | US | disclosed |
| EP-2178857-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009005729-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053918-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | GSK3A 149/4885GSK3B 151/4885ELANE 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.